Announcements Trials
Browse Landscape

Phase

Phase 2 6

Status

Unknown 6

Sponsor Class

OTHER 70UNKNOWN 6OTHER_GOV 6INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 5Genitourinary 1CNS 1

Conditions

Breast Neoplasms 4Carcinoma, Transitional Cell 1Brain Neoplasms 1Advanced Breast Cancer 1

Interventions

S 1 (combination) 12Capecitabine 11Paclitaxel 9Cisplatin 9apatinib 8Oxaliplatin 8pyrotinib 6nimotuzumab 6130-nm albumin-bound paclitaxel 6titanium silicide 5sintilimab 5camrelizumab 5anlotinib 5Etoposide 5Docetaxel 5Carboplatin 5Trastuzumab 4Radiotherapy, Intensity-Modulated 4Irinotecan 4Bevacizumab 4Albumin-Bound Paclitaxel 4nedaplatin 3Vinorelbine 3Temozolomide 3Tegafur 3Taxes 3Radiosurgery 3Gemcitabine 3Fluorouracil 3Epirubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × UNKNOWN × pyrotinib × Clear all
NCT05318339 2022-04-08

A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

ChineseAMS

Phase 2 Unknown
30 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT05020964 2021-08-25

Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

ChineseAMS

Phase 2 Unknown
68 enrolled
Breast

Advanced Breast Cancer

NCT04033172 2019-07-25

Pyrotinib

ChineseAMS

Phase 2 Unknown
40 enrolled
Breast

Breast Neoplasms

NCT03933982 2019-05-29

Pyrotinib

ChineseAMS

Phase 2 Unknown
30 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03923166 2019-04-22

Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer

ChineseAMS

Phase 2 Unknown
35 enrolled
Breast

Breast Neoplasms

NCT03923179 2019-04-22

Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

ChineseAMS

Phase 2 Unknown
32 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡